Á¾¾çÇÐ °øµ¿ ¿¬±¸ ¹× ¶óÀ̼±½Ì °è¾à(2020-2025³â)
Oncology Collaboration and Licensing Deals 2020-2025
»óǰÄÚµå : 1708060
¸®¼­Ä¡»ç : Current Partnering, a brand of Biopharma Research Ltd.
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 1500+ Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,995 £Ü 7,227,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,995 £Ü 10,121,000
PDF (Multi User License - 2 to 5 Users) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 2-5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,995 £Ü 11,567,000
PDF (Company Wide License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Á¾¾çÇÐ Á¦ÈÞ ¹× ¶óÀ̼±½º °è¾àÀº ¼¼°è ÁÖ¿ä ¹ÙÀÌ¿À±â¾÷ÀÌ Ã¼°áÇÑ Á¾¾çÇÐ ºÐ¾ß °è¾à¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ÀÌÇØ¿Í ÇÔ²² Àü·Ê ¾ø´Â Á¢±Ù¼ºÀ» Á¦°øÇÕ´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­´Â 2020-2025³â 3,350°ÇÀÇ Á¾¾çÇÐ °ü·Ã ÇÁ·ÎÁ§Æ®¸¦ »ó¼¼ÇÏ°Ô ºÐ¼®Çß½À´Ï´Ù.

´ç»çÀÚ °£¿¡ ¹ßÇ¥µÈ °Å·¡ÀÇ ÁöºÒ Á¶°Ç¿¡ ´ëÇÑ ¾×¼¼½º¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ µ¥ÀÌÅÍ´Â ÁöºÒ Á¶°Ç ¹× ±âŸ °Å·¡ Á¶°Ç¿¡ ´ëÇÑ À¯¿ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

ÆÄÆ®³Ê Èĺ¸ÀÚ°¡ Çù»óÇÑ °Å·¡ Á¶°ÇÀÇ À¯¿¬¼ºÀ» ÀÌÇØÇϸé Çù»ó °úÁ¤¿¡¼­ ¹«¾ùÀ» ´Þ¼ºÇÒ ¼ö ÀÖ´ÂÁö¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ¸¹Àº Áß¼Ò±â¾÷Àº ÁöºÒ Á¶Ç×ÀÇ ¼¼ºÎ »çÇ×À» ¿ä±¸ÇÒ °ÍÀ¸·Î ¿¹»óµÇÁö¸¸, ÁöºÒÀÌ ¾î¶»°Ô ¹ß»ýÇÏ°í ±Ç¸®°¡ ¾î¶»°Ô ¾çµµµÇ´ÂÁö¿¡ °üÇØ¼­´Â ¼¼ºÎ »çÇ׿¡ ¾Ç¸¶°¡ ¼û¾îÀÖ½À´Ï´Ù.

Current AgreementsÀÇ °Å·¡ ¹× Á¦ÈÞ µ¥ÀÌÅͺ£À̽º¿¡ ±â·ÏµÈ 2020³â ÀÌÈÄ ¹ßÇ¥µÈ Á¦ÈÞ ¹× ¶óÀ̼±½º °è¾àÀÇ Á¾ÇÕÀûÀÎ ¸®½ºÆ®À» ´ã°í ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ Ã¹ ¹øÂ° Àå¿¡¼­´Â Á¾¾çÇÐ ºÐ¾ßÀÇ °Å·¡¿Í ºñÁî´Ï½º Ȱµ¿¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù. 1Àå¿¡¼­´Â ÀÌ º¸°í¼­ÀÇ ¼Ò°³¸¦, 2Àå¿¡¼­´Â Á¾¾çÇÐ ºÐ¾ßÀÇ °Å·¡ µ¿ÇâÀ» ºÐ¼®Çß½À´Ï´Ù.

3Àå¿¡¼­´Â Á¾¾çÇÐ ºÐ¾ß¿¡¼­ ü°áµÈ °Å·¡ÀÇ À繫Àû °Å·¡ Á¶°Ç°ú °³¹ß ´Ü°è¸¦ ¹ßÇ¥ÇÕ´Ï´Ù. °Å·¡´Â ¸®½ºÆ®È­µÇ¾î ÀÖÀ¸¸ç, °è¾à±Ý, °è¾à ÀϽñÝ, ¸¶ÀϽºÅæ, ·Î¿­Æ¼º°·Î ±¸ºÐµÇ¾î ÀÖ½À´Ï´Ù.

4Àå¿¡¼­´Â Á¾¾çÇÐ ºÐ¾ß °Å·¡¿¡ °¡Àå Àû±ØÀûÀÎ »óÀ§ 25°³ ¹ÙÀÌ¿ÀÁ¦¾à±â¾÷¿¡ ´ëÇÑ ¸®ºä¸¦ ¼ö·ÏÇÏ¿´À¸¸ç, SEC¿¡ °ø½ÃµÈ °è¾à¼­°¡ ÀÖ´Â °Ç¿¡ ´ëÇØ´Â Current AgreementsÀÇ °Å·¡ ¹× Á¦ÈÞ µ¥ÀÌÅͺ£À̽º¸¦ ÅëÇØ ¿Â¶óÀÎÀ¸·Î °è¾à¼­¿¡ Á¢¼ÓÇÒ ¼ö ÀÖ´Â ¸µÅ©¸¦ Á¦°øÇÕ´Ï´Ù. ¿Â¶óÀÎÀ¸·Î °è¾à¼­¿¡ Á¢¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.

5Àå¿¡¼­´Â °è¾à ¹®¼­°¡ ÀÔ¼ö °¡´ÉÇÑ 2020³â ÀÌÈÄ Ã¼°á ¹× ¹ßÇ¥µÈ Á¾¾çÇÐ ºÐ¾ß °Å·¡¸¦ Á¾ÇÕÀûÀÌ°í »ó¼¼ÇÏ°Ô °ËÅäÇϰí ÀÖ½À´Ï´Ù. °¢ °Å·¡ÀÇ Á¦¸ñÀº À¥ ¸µÅ©¸¦ ÅëÇØ ½ÇÁ¦ °è¾à ¹®¼­ÀÇ ¿Â¶óÀÎ ¹öÀüÀ¸·Î ¿¬°áµÇ¸ç, °¢ °è¾à ¹®¼­¿¡ ¿Âµð¸Çµå ¹æ½ÄÀ¸·Î ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖ½À´Ï´Ù.

6Àå¿¡¼­´Â Á¾¾çÇÐ ¿µ¿ªÀÇ Á¾ÇÕÀûÀÎ µð·ºÅ丮¸¦ Ÿ±êº°·Î Á¤¸®ÇØ ³õ¾Ò½À´Ï´Ù.

¶ÇÇÑ 2020³â ÀÌÈÄ Á¾¾çÇÐ ºÐ¾ßÀÇ °è¾à µ¿Çâ°ú Ȱµ¿À» º¸¿©ÁÖ´Â µµÇ¥µµ ´Ù¼ö ¼ö·ÏµÇ¾î ÀÖ½À´Ï´Ù.

¶ÇÇÑ Á¾ÇÕÀûÀÎ °Å·¡ µð·ºÅ丮´Â ±â¾÷ A-Z ¹× ±â¼ú À¯Çüº°·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. °¢ °Å·¡ Á¦¸ñÀº À¥ ¸µÅ©¸¦ ÅëÇØ ¿Â¶óÀÎ ¹öÀüÀÇ °Å·¡ ±â·Ï·Î ¿¬°áµÇ¸ç, °¡´ÉÇÑ °æ¿ì °è¾à ¹®¼­µµ °Ô½ÃµÇ¾î ÀÖÀ¸¸ç, °¢ °è¾à ¹®¼­¿¡ ´ëÇÑ ¿Âµð¸Çµå Á¢±ÙÀÌ ¿ëÀÌÇÕ´Ï´Ù.

ÁÖ¿ä ÀåÁ¡

Á¾¾çÇÐ ºÐ¾ßÀÇ °øµ¿ ¿¬±¸ ¹× ¶óÀ̼±½º °è¾àÀº µ¶Àڵ鿡°Ô ´ÙÀ½°ú °°Àº ÁÖ¿ä ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. :

Á¶»ç ¹üÀ§

º¸°í¼­ ³»¿ë

¸ñÂ÷

°³¿ä

Á¦1Àå ¼­·Ð

Á¦2Àå Á¾¾çÇÐ °Å·¡ÀÇ µ¿Çâ

Á¦3Àå Á¾¾çÇÐ Á¦ÈÞÀÇ À繫 °Å·¡Á¶°Ç

Á¦4Àå Á¾¾çÇÐÀÇ ÁÖ¿ä °Å·¡¿Í µô¸ÞÀÌÄ¿

Á¦5Àå Á¾¾çÇÐ °è¾à ¹®¼­ µð·ºÅ丮

Á¦6Àå Ä¡·á Ç¥Àûº° Á¾¾çÇÐ °Å·¡

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the oncology deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of 3,350 oncology deals from 2020 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in oncology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the oncology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in oncology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of oncology deals signed and announced since 2020 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of oncology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in oncology deal making since 2020.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

Report scope

Oncology Collaboration and Licensing Deals includes:

In Oncology Collaboration and Licensing Deals, the available deals are listed by:

Analyzing contract agreements allows due diligence of:

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in oncology dealmaking

Chapter 3 - Financial deal terms for oncology partnering

Chapter 4 - Leading oncology deals and dealmakers

Chapter 5 - Oncology contract document directory

Chapter 6 - Oncology dealmaking by therapeutic target

Table of figures

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â